SYSTEMATIC REVIEW article

Front. Surg., 22 April 2022

Sec. Visceral Surgery

Volume 9 - 2022 | https://doi.org/10.3389/fsurg.2022.882173

Coating of Intestinal Anastomoses for Prevention of Postoperative Leakage: A Systematic Review and Meta-Analysis

  • 1. Department of Surgery, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Bavaria, Germany

  • 2. Institute of Diagnostic and Interventional Radiology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Bavaria, Germany

  • 3. Department of Orthopaedics and Sports Orthopaedics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Bavaria, Germany

Abstract

Background:

For several decades, scientific efforts have been taken to develop strategies and medical aids for the reduction of anastomotic complications after intestinal surgery. Still, anastomotic leakage (AL) represents a frequently occurring postoperative complication with serious consequences on health, quality of life, and economic aspects. Approaches using collagen and/or fibrin-based sealants to cover intestinal anastomoses have shown promising effects toward leak reduction; however, they have not reached routine use yet. To assess the effects of covering intestinal anastomoses with collagen and/or fibrin-based sealants on postoperative leakage, a systematic review and meta-analysis were conducted.

Method:

PubMed, Web of Science, Cochrane Library, and Scopus (01/01/1964 to 17/01/2022) were searched to identify studies investigating the effects of coating any intestinal anastomoses with collagen and/or fibrin-based sealants on postoperative AL, reoperation rates, Clavien–Dindo major complication, mortality, and hospitalization length. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.

Results:

Overall, 15 studies (five randomized controlled trials, three nonrandomized intervention studies, six observational cohort studies) examining 1,387 patients in the intervention group and 2,243 in the control group were included. Using fixed-effects meta-analysis (I2 < 50%), patients with coated intestinal anastomoses presented significantly lower AL rates (OR = 0.37; 95% CI 0.27–0.52; p < 0.00001), reoperation rates (OR, 0.21; 95% CI, 0.10–0.47; p = 0.0001), and Clavien–Dindo major complication rates (OR, 0.54; 95% CI, 0.35–0.84; p = 0.006) in comparison to controls, with results remaining stable in sensitivity and subgroup analyses (stratified by study design, age group, intervention used, location of anastomoses, and indication for surgery). The length of hospitalization was significantly shorter in the intervention group (weighted mean difference (WMD), −1.96; 95% CI, −3.21, −0.71; p = 0.002) using random-effects meta-analysis (I2 ≥ 50%), especially for patients with surgery of upper gastrointestinal malignancy (WMD, −4.94; 95% CI, −7.98, −1.90; p = 0.001).

Conclusion:

The application of collagen-based laminar biomaterials or fibrin sealants on intestinal anastomoses can significantly reduce postoperative rates of AL and its sequelae. Coating of intestinal anastomoses could be a step toward effective and sustainable leak prevention. To assess the validity and robustness of these findings, further clinical studies need to be conducted.

Introduction

In the field of visceral surgery, both patients and surgeons are still challenged with a very common and potentially devastating postoperative complication, namely, anastomotic leakage (AL). Whether the intestinal anastomoses were performed in the upper or lower gastrointestinal tract (GIT), postoperative AL accompanies a significant proportion of intestinal surgical procedures (110). Colorectal procedures, for instance, present with AL rates of up to 25.6% (4, 8, 9), and esophageal or esophagogastric procedures present with AL rates as high as 19.5% (6, 7). AL rates among patients with malignancies are even associated with local (11) and distant (12) tumor recurrences. Furthermore, AL has been shown to increase the total clinical and economic burden by 0.6–1.9 times for patients undergoing intestinal surgery for colorectal cancer (13).

In this context, it is not surprising that substantial scientific efforts have been invested now for over half a century to develop strategies and medical aids to reduce or even prevent the development of postoperative AL. The first approach toward covering and hereby mechanically strengthening the newly built intestinal anastomosis was to apply cyanoacrylate preparations, better known as surgical glues initially tested on skin wounds in military settings. Their rapid formation of a stable but flexible connection with intestinal tissue was considered advantageous (14, 15). Other experimental approaches utilized sterile polyethylene plastic sheets (16), fibrin adhesives (17, 18), and collagen fleeces (17) to additionally support the anastomoses. The most promising adhesives, however, are fibrin sealants, as these have been acknowledged across various surgical specialties and were approved in their liquid form by the FDA in 1998 (19).

Biodegenerable and absorbable fibrin sealants consist of two components: sealer protein solution (human fibrinogen, factor XIII, and protease inhibitor aprotinin) and thrombin solution (human thrombin and calcium chloride). Upon application of the sealant to the site of anastomosis, thrombin transforms fibrinogen into insoluble fibrin monomers, which are then polymerized in the presence of factor XIII to a stable fibrin network within minutes. Protease inhibitor aprotinin protects this network from plasmin-mediated proteolysis. Simulating the last step of the coagulation cascade, fibrin sealants are used to initiate hemostasis, seal tissue, and promote the healing processes (20).

With the 2010 FDA approval of a fibrin sealant-coated equine collagen matrix (21) used primarily for hemostatic purposes, experimental approaches studying its potentially beneficial effect on anastomotic healing were initiated. Within the last decade, mainly animal studies were conducted, revealing promising effects on reducing postoperative AL and mortality rates upon using either fibrin sealants or collagen-based laminar biomaterials (2233). For many years, just a small number of experimental trials have been available, examining the effect of these sealants on human populations (3440). Until now, no meta-analysis has been conducted examining the effect of externally covering intestinal anastomoses with collagen-based laminar biomaterials or fibrin sealants on postoperative AL and its consequences within a human population.

Therefore, the aim of this study was to systematically evaluate the efficacy of externally coating intestinal anastomoses of the upper and lower GIT, regardless of location or underlying disease, with collagen-based laminar biomaterials and/or fibrin sealants in reducing postoperative AL rates and its accompanying complications. A systematic review and meta-analysis of existing human studies was conducted, comparing the summary effect size, calculating the pooled odds ratios (ORs) with 95% confidence intervals (CIs), and performing subgroup analyses stratified by study design, coating utilized, age group, indication for surgery, and location of anastomoses.

Methods

This systematic review and meta-analysis was conducted and reported according to the recommendations in the Cochrane Handbook for Reviews of Interventions (41) and the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) Statement 2020 (42).

Eligibility Criteria

For this study, all observational studies (prospective or retrospective comparative cohort or case–control studies), nested case–control studies, randomized controlled trials (RCTs), nonrandomized controlled trials, and cross-sectional studies were included based on the following criteria: examined a human population—regardless of age, sex, or underlying condition; published only in English, German, or Spanish language; available as either abstract or full-text article in the medical databases between 01/01/1964 and 17/01/2022; included humans undergoing any intestinal surgical procedure with the formation of any kind of intestinal anastomoses with focus on the upper and lower GIT; the intervention group included patients who received an intestinal anastomosis (regardless of anastomotic technique) coated or reinforced with either a collagen-based laminar biomaterial or a fibrin sealant (synthetic or animal derived, with or without additional substances embedded, regardless of the manufacturer); control group included patients who received an intestinal anastomosis (regardless of anastomotic technique) not coated or reinforced with any product; and depicted postoperative clinical outcomes, including but not restricted to, AL, reoperation and mortality rates, major complication rates (grades III–V) according to the Clavien–Dindo classification of surgical complications (43) (C-DMC), and length of hospital stay.

Exclusion criteria comprised studies representing reviews or meta-analyses, case reports or case series, animal studies, ex vivo or in vitro studies; gastrointestinal surgical procedures without the formation of an intestinal anastomosis; hepatobiliary anastomoses (e.g., pancreaticointestinal anastomoses, biliodigestive anastomoses); closure of transmural and nontransmural intestinal defects; intestinal stumps or pouches; coating of anastomosis in an operative revision, secondary to AL or fistula formation; and any kind of anastomotic coatings or sealants not based on collagen and/or fibrin.

Search Strategy

We conducted a comprehensive systematic literature search for studies published in the electronic medical databases PubMed (MEDLINE), Web of Science, Scopus, and Cochrane Library using predefined search items, further specified in Supplementary Table S1.

To ensure that potentially relevant studies were not missed, reference lists of reviews and included studies were examined manually, and additional web search was conducted. In case of ambiguous or inadequate data presentation, we contacted these studies’ authors to provide the required information. The final search was conducted on 17/01/2022.

Selection Process

Study selection was performed by two investigators (surgical residents: K.C. and F.S.) independently. All studies identified in the search process were exported to the reference management tool EndNote X9 (The EndNote Team, Clarivate 2013, Philadelphia, PA, USA).

Duplicates were removed by computer-based methods, followed by a secondary manual exclusion. Titles and abstracts were assessed manually and excluded in accordance with our predefined eligibility criteria. Abstracts and full-text articles correlating with these criteria were retrieved and further evaluated for eligibility. Disagreements concerning eligibility were discussed and resolved in consensus with a third investigator (surgical specialist: P-A.N.), who independently assessed the accuracy of the search results.

Data Collection Process

Two investigators (K.C. and F.S.) independently performed data collection and analysis onto a Microsoft Excel spreadsheet (Home and Student 2019 edition; Microsoft, Redmond, WA, USA), and a third investigator (radiology resident: S.R.) independently assessed the accuracy of the extracted data. In case of any discrepancies, the extracted data were discussed and resolved in consensus with the fourth investigator (P-A.N.) acting as an arbitrator.

Data Extraction

For each study, we collected the following data, if available: author, year, and country of publication; study design and inclusion period; ethical approval and funding; inclusion and exclusion criteria; number of patients in the intervention and control group; baseline characteristics such as age, sex, and body mass index; surgical characteristics: indication for surgery, surgical intervention and technique, and anastomoses (number, location, and technique); collagen-based biomaterial or fibrin sealant used in the intervention group; and any additional intervention. Study and patients’ characteristics are presented in Table 1, and surgical characteristics are given in Table 2.

Table 1

AuthorYearCountryStudy designAge groupNumber of patients, nAnastomotic coating
(intervention group)
Indication for surgery
IC
Brehant et al. (50)2013FranceRCSAdult202404Collatamp Sponge (C-BLB)Colorectal cancer;
Benign lesions
Marano et al. (54)2016ItalyRCSAdult2834TachoSil (C-BLB)Gastric cancer;
Esophagogastric junction cancer
Torres-Melero et al. (58)2016SpainNRSAdult2227Fibrin-coated collagen sponge (C-BLB)Peritoneal carcinomatosis (colorectal cancer)
Fernandez et al. (34)1996SpainRCTAdult4244Tissucol (FS)Gastric adenocarcinoma
Grieder et al. (51)a2010SwitzerlandPilot-studyAdult118113Fibrin Glue (FS)Colorectal cancer
Huang et al. (52)2021ChinaRCSAdult86141Bioseal (FS)Squamous cell or adenocarcinoma of the thoracic or esophagogastric junction
Huh et al. (36)2010KoreaPCSAdult104119Tissucol or Greenplast (FS)Rectal cancer
Kim et al. (53)2013KoreaRCSAdult414734Tissucol or Greenplast (FS)Rectal cancer
Liu et al. (37)2003United StatesNRSAdult120360Tisseel (FS)Obesity (bariatric surgery)
Oliver et al. (55)2012SpainRCTAdult5252Tissucol Duo (FS)Different conditions (high-risk anastomoses)
Saldaña-Cortés et al. (38)2009MexicoNRSPediatric1424Quixil (FS)Caustic esophageal injury
Sdralis et al. (56)2019GreeceRCTAdult3522Tisseel (FS)Adenocarcinoma of the distal esophagus or esophagogastric junction
Sieda et al. (57)2015EgyptPCSAdult3535Commercial Fibrin SealantMalignant colonic obstruction;
Nonmalignant colonic obstruction
Silecchia et al. (39)2006ItalyRCTAdult93111Tissucol (FS)Obesity (bariatric surgery)
Upadhyaya et al. (40)2007IndiaRCTPediatric2223Tisseel (FS)Esophageal atresia with tracheoesophageal fistula

Study and patient characteristics.

RCS, Retrospective cohort study; PCS, prospective cohort study; RCT, randomized controlled trial; NRS, nonrandomized study; I, Intervention group (coated or reinforced anastomoses); C, control group; C-BLB, collagen-based laminar biomaterial; FS, fibrin sealant; Benign lesions, diverticulitis, inflammatory bowel disease, or other lesions; nonmalignant colonic obstruction, perforated diverticulum, inflammatory bowel disease, volvulus, fecal fistula, bands.

aAbstract.

Table 2

AuthorYearOpen/laparoscopicbSurgical interventionSite and technique of anastomosis
Ic/CcAnastomotic covering/reinforcement (Ic)
Brehant et al. (50)2013✓/✓Colon or colorectal resectionIntestinal anastomosisCollatamp (10 × 10 cm)
Marano et al. (54)2016✓/—Total or distal gastric resection;
Distal esophagectomy and total gastrectomy
Mechanical end-to-side esophagojejunal anastomosis (25 mm anvil head circular stapler);
mechanical side-to-end gastrojejunal anastomosis
(28 mm anvil head circular stapler)
TachoSil
(9.5 × 4.8 × 0.5 cm with two seromuscular stitches)
Torres-Melero et al. (58)2016N/ADebulking colon resectionMechanical intestinal anastomosisFibrin-coated collagen sponge (9.5 × 4.8 cm)
Fernandez et al. (34)1996N/ACurative R2 or extended gastrectomyMechanical end-to-side esophagojejunal anastomosis (Roux-en-Y jejunal loop used; tobacco pouch formed manually)Tissucol (applied on both surfaces during approximation of anvil to the Stapler Cartridge)
Grieder et al. (51)a2010✓/✓Colorectal resectionMechanical intestinal anastomosis (approximately 10 cm above anal verge)Fibrin glue (1 mL; applied between pressure plates of stapler, fired after 2–3 min)
Huang et al. (52)2021✓/✓McKeown esophagectomyMechanical end-to-side esophagogastric anastomosis (inverted; circular stapler: EEA 21 or 25 mm)Bioseal (2.5 mL)
Huh et al. (36)2010—/✓Low anterior rectal resectionDouble-stapled colorectal anastomosisTissucol or Greenplast (1–2 mL)
Kim et al. (53)2013✓/✓Low anterior rectal resection with total mesorectal excisionDouble-stapled colorectal anastomosisTissucol or Greenplast (1–2 mL)
Liu et al. (37)2003✓/✓Roux-en-Y-gastric bypassHand-sewn gastrojejunal anastomosisTisseel (5 mL; perivisceral fat pad glued to anterolateral part of anastomosis)
Oliver et al. (55)2012N/AEsophageal resection; Roux-en-Y-gastric bypass; gastrectomy; rectal resection; intestinal resection of obstructed segmentIntestinal anastomosis (according to procedure)Tissucol
Saldaña-Cortés et al. (38)2009✓/−Colon interposition for esophageal reconstructionHand-sewn, single layer, end-to-side cervicocolic anastomosis covered (4-0 Vicryl)Quixil (3–4 mL)
Sdralis et al. (56)2019✓/✓Two-stage esophagectomy—Ivor-Lewis procedureIntrathoracic mechanical end-to-side esophagogastric anastomosis (circular stapler: CDH 25 OR 29 mm)Tisseel
Sieda et al. (57)2015✓/—Enterocolic resection or colectomyHand-sewn, single layer, enterocolic or colocolic anastomosis (continuous suture, 3-0 Vicryl)Fibrin sealant
Silecchia et al. (39)2006✓/—Roux-en-Y-gastric bypassMechanical or hand-sewn gastrojejunal anastomosis
(Gagner technique with circular stapler 25 EEA; linear stapler; two-layer continuous suture);
jejunal anastomosis
Tissucol (2- or 5-mL)
Upadhyaya et al. (40)2007✓/—Esophageal reconstructionHand-sewn, single layer, end-to-side esophageal anastomosis (5-0 Vicryl)Tisseel

Surgical characteristics.

N/A, Not available; mm, millimeter; cm, centimeter; mL, milliliter; ✓, yes; –, no; I, intervention group (coated or reinforced anastomoses); C = Control Group.

aAbstract.

To provide an implication on and utilization in surgical practice, data on postoperative AL, reoperation, C-DMC, mortality rate, and the length of hospitalization were collected (Table 3).

Table 3

AuthorYearAnastomotic leakage,
n (%)
Reoperation,
n (%)
Clavien-Dindo major complications
(43), n (%)
Length of hospitalization,
mean (SD)b;
in Days
Mortality,
n (%)
IcCcIcCcIcCcIcCcIcCc
Brehant et al. (50)2013N/AN/AN/AN/A↓18 (9)↑67 (16.6)N/AN/A
Marano et al. (54)20160 (0)4 (11.8)N/AN/AN/AN/A↓ 14.7 ± 4.3↑ 19.9 ± 5.60 (0)0 (0)
Torres-Melero et al. (58)20160 (0)3 (11.1)1 (4.6)3 (11.1)N/AN/AN/AN/AN/AN/A
Fernandez et al. (34)19960 (0)4 (9)0 (0)0 (0)N/AN/AN/AN/A0 (0)0 (0)
Grieder et al. (51)a20105 (4.2)9 (8)3 (2.5)9 (8)N/AN/AN/AN/AN/AN/A
Huang et al. (52)2021↓4(4.7)↑28(19.4)N/AN/A12 (14)28 (20)↓12.11 ± 3.86↑15.51 ± 9.540 (0)2 (1.4)
Huh et al. (36)20106 (5.8)13 (11)N/AN/AN/AN/A9.46 ± 2.379.81 ± 3.03N/AN/A
Kim et al. (53)2013↓17(4.1)↑59(8)0 (0)7 (1)N/AN/AN/AN/AN/AN/A
Liu et al. (37)2003↓0(0)↑8(2.2)↓3 (2.5)↑12 (3.3)N/AN/AN/AN/AN/AN/A
Oliver et al. (55)2012↓7(13.5)↑15(28.9)N/AN/AN/AN/AN/AN/A3 (5.8)4 (7.7)
Saldaña-Cortés et al. (38)20094 (28.6)12 (50)N/AN/AN/AN/A12.6 ± 2.612.9 ± 2.61 (7.1)1 (4.1)
Sdralis et al. (56)20195 (14.3)3 (13.7)N/AN/AN/AN/AN/AN/AN/AN/A
Sieda et al. (57)20153 (8.6)7 (20)N/AN/AN/AN/A5 ± 1.77 ± 2.3N/AN/A
Silecchia et al. (39)20060 (0)2 (1.8)↓0 (0)↑8 (7.2)N/AN/A7.0 ± 1.67.0 ± 1.80 (0)0 (0)
Upadhyaya et al. (40)2007↓2(9.1)↑10(43.5)N/AN/AN/AN/AN/AN/A2 (9.1)6 (26)

Postoperative outcomes.

N/A, Not available; ↓, significantly lower; ↑, significantly higher.

I, Intervention group (coated or reinforced anastomoses); and C, control group.

aAbstract.

bIf given in “median (interquaratile range)” or “median (range: minimum - maximum”, values were converted using the Box-Cox (BC) method of McGrath et al. 2020 (47) to estimate the sample mean and standard deviation.

The bold indicates significant outcomes.

Risk of Bias Assessment

The quality of the included studies was assessed by two investigators (K.C. and F.S.) independently. Systematic assessment of the risk of bias for randomized controlled studies and nonrandomized studies of interventions was conducted using the Risk of Bias 2 (RoB 2) tool (44) and the Risk Of Bias In Nonrandomized Studies of Interventions (ROBINS-I) tool (45), according to the recommendations in the Cochrane Handbook for Reviews of Interventions (41). The Newcastle–Ottawa Scale (NOS) for cohort studies (46), a commonly used and established tool, was used to evaluate the quality of included observational studies. We defined any study with an NOS score of >7 as high quality, 5–7 as moderate, and <5 as low quality. Any disagreements were resolved in consensus with the third investigator (S.R.).

Synthesis Method

All statistical analyses in this review were carried out using Review Manager software version 5.3. (Nordic Cochrane Centre, Copenhagen, Denmark) and the JASP Team (2021; JASP, version 0.16). Results with a p-value of <0.05 are considered significant. Values given in the unit “median (interquaratile range)” or “median (range: minimum - maximum)” were converted using the Box-Cox method of McGrath et al. (48) to estimate the sample mean and standard deviation. Heterogeneity across studies was analyzed using the statistical I2 test, considering I2 ≥ 50% as substantial heterogeneity (48). In case of substantial heterogeneity (I2 ≥ 50%), the random-effects model was used to conduct the meta-analyses; for I2 < 50%, the fixed-effects model was utilized.

Potential publication bias was examined using Egger’s test (49) for funnel plot asymmetry for outcomes including ≥10 studies, as it is not recommended to conduct the test in the case of fewer studies included (41). To evaluate the stability of our outcomes, we conducted a sensitivity analysis by evaluating the impact of excluding one study at a time on the pooled OR, regardless of the observed heterogeneity. Subgroup analyses were planned a priori to assess potential risk factors on studied postoperative outcomes and patient groups at higher risk for complications. The predefined subgroups, assessed in secondary analysis, were stratified by study design, intervention used (collagen-based laminar biomaterials and/or fibrin sealants), age group (adult or pediatric), location of anastomoses (esophagus, stomach, small intestine, colon, and/or rectum), and indication for surgery. Differences in the outcomes across these subgroups were assessed and reported using the test for subgroup differences (TSD).

In subject to the calculated I2 percentage, either the random-effects model (I2 ≥ 50%) or the fixed-effects model (I2 < 50%) was used to summarize and depict pooled ORs with 95% CIs in a forest plot.

Results

In summary, we identified 1,581 studies through electronic database search and 11 studies through citation and website search, out of which 382 duplicates were removed. Title and abstracts of 1,199 studies were screened manually, and 1,142 studies lacking eligibility were excluded. Of 57 eligible studies thus-acquired for full-text analysis, 35 could not be retrieved, leaving 22 studies originating from the database search and 11 studies identified by other methods. After full-text analysis, 10 of 22 studies were excluded: five studies without a control group, four studies using other interventions, and one study with an irrelevant endpoint. Of the 11 studies identified through citation and website search, eight studies without the formation of an anastomosis were excluded. Finally, 15 studies (34, 3640, 5058) were analyzed quantitatively and qualitatively for this systematic review and included in our meta-analyses (Figure 1).

Figure 1

Study Characteristics

This systematic review and meta-analysis evaluates five RCTs (34, 39, 40, 55, 56), three nonrandomized intervention studies (NRSs) (37, 38, 58), four retrospective cohort studies (RCSs) (50, 5254), two prospective cohort studies (PCS) (36, 57), and one abstract (51). These studies were published between 1996 and 2021 and were conducted in China (52), Egypt (57), France (50), Greece (56), India (40), Italy (39, 54), Korea (36, 53), Mexico (38), Spain (34, 55, 58), Switzerland (51), and the USA (37).

Of 3,630 patients included in 15 studies, 1,387 patients received an intervention, while 2,243 served as a control. To cover the anastomoses, collagen-based laminar biomaterials were utilized in 252 patients (50, 54, 58), and fibrin sealants were utilized in 1,135 cases (34, 3740, 5153, 5557). The majority of studies examined adult patients (34, 36, 37, 39, 5058) undergoing intestinal surgery for malignant tumors (34, 36, 5054, 5658), benign lesions (such as diverticulitis, inflammatory bowel disease, or any kind of nonmalignant intestinal obstruction) (50, 55, 57), or bariatric surgery due to morbid obesity (37, 39). Pediatric patients were examined in two studies (38, 40); indications for surgery were either congenital esophageal atresia with tracheoesophageal fistula (40) or caustic esophageal injury (38) (Table 1).

In all cases, regardless of the anastomotic location or technique, intestinal anastomoses of patients in the intervention group were either reinforced or covered externally with either collagen-based laminar biomaterials (Collatamp or TachoSil) (50, 54, 58) or fibrin sealants (Tisseel, Tissucol, Greenplast, Bioseal or Quixil) (34, 3640, 5153, 5557). Patients in the control group received the same surgical procedure as the intervention group but without covering the anastomoses with any substance. Detailed surgical characteristics, including surgical intervention and anastomotic technique, are depicted in Table 2.

Postoperative AL was assessed in 14 studies (34, 3640, 5158), out of which five (37, 40, 52, 53, 55) found a significantly lower AL rate within the intervention group. Reoperation and C-DMC rates were found to occur significantly less common in patients with sealed anastomoses in two (37, 39) out of six and one (50) out of two studies, respectively. Two out of six studies (52, 54) reported significantly longer hospitalizations for patients in the control group. Differences between the study groups in regard to mortality rates could not be detected in seven studies (34, 3840, 52, 54, 55) (Table 3).

Risk of Bias Assessment

Risk of bias assessment was performed for all but one study (51), representing an abstract instead of a full-text article (Supplementary Table S2).

To assess the risk of bias for included RCTs (34, 39, 40, 55, 56), the RoB 2 tool (44) was utilized, and for nonrandomized studies (37, 38, 58), the ROBINS-I tool (45) was applied, according to the recommendations in the Cochrane Handbook for Reviews of Interventions (41). All of these studies presented either some concerns (RCT) (34, 39, 40, 55, 56) or moderate risk of bias (NRS) (37, 38, 58).

The NOS for cohort studies (46) was used to assess the quality of the six included observational studies (36, 50, 5254, 57). The risk of bias based on this quality assessment presented the majority of studies (36, 50, 5254) as being of moderate quality (n = 5; NOS score 6–7), while one study (57) appeared to be low in quality (NOS < 5).

Result of Synthesis

Postoperative Anastomotic Leakage Rates

Overall, 14 studies (34, 3640, 5158) reported postoperative AL rates occurring in 53 (4.5%) of 1,185 patients in the intervention group and 177 (9.6%) of 1,839 patients in the control group. The AL rate was significantly lower for patients with coated anastomoses using fixed-effects meta-analysis (OR, 0.37; 95% CI, 0.27–0.52; p < 0.00001) (Figure 2).

Figure 2

Studies were homogeneous (I2 = 0%; p = 0.84), and no publication bias was observed (Egger’s test p = 0.227). Observed results remained stable throughout sensitivity analyses, excluding one study at a time (Table 4).

Table 4

Postoperative anastomotic leakageOdds ratio (OR): fixed-effects modelHeterogeneityEggers test
OverallOR, 0.37; 95% CI, 0.27–0.52; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.84p = 0.227
Sensitivity analyses
Excluded studyOR: fixed-effects modelHeterogeneity
Fernandez et al. (34)OR, 0.38; 95% CI, 0.28–0.53; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.83
Grieder et al. (51)OR, 0.36; 95% CI, 0.26–0.51; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.79
Huang et al. (52)OR, 0.40; 95% CI, 0.29–0.57; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.90
Huh et al. (36)OR, 0.36; 95% CI, 0.26–0.51; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.79
Kim et al. (53)OR, 0.33; 95% CI, 0.22–0.48; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.84
Liu et al. (37)OR, 0.38; 95% CI, 0.27–0.53; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.80
Marano et al. (54)OR, 0.38; 95% CI, 0.28–0.53; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.82
Oliver et al. (55)OR, 0.37; 95% CI, 0.27–0.53; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.77
Saldaña-Cortés et al. (38)OR, 0.37; 95% CI, 0.27–0.52; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.77
Sdralis et al. (56)OR, 0.36; 95% CI, 0.26–0.50; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.89
Sieda et al. (57)OR, 0.37; 95% CI, 0.27–0.52; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.78
Silecchia et al. (39)OR, 0.38; 95% CI, 0.27–0.52; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.78
Torres-Melero et al. (58)OR, 0.37; 95% CI, 0.27–0.53; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.80
Upadhyaya et al. (40)OR, 0.39; 95% CI, 0.28–0.54; p < 0.00001 [↓(I); ↑(C)]I2 = 0%; p = 0.90

Fixed-effects meta-analysis for postoperative anastomotic leakage in the intervention and control group.

↓, Significantly lower; ↑, significantly higher; I, intervention group (coated or reinforced anastomoses); C, control group.The bold indicates significant outcomes.

Subgroup analyses found no subgroup differences for subgroups stratified by study design (TSD: p = 0.74), intervention used (TSD: p = 0.33), age group (TSD: p = 0.40), anastomotic location (TSD: p = 0.63), indication for surgery (TSD: p = 0.66), and its subclassification (TSD: p = 0.45) (Table 5).

Table 5

Subgroup analyses
SubgroupOdds ratio (OR): fixed-effects modelTest for subgroup difference
Study designp = 0.75
 RCTOR, 0.33; 95% CI, 0.17–0.65; p = 0.001 [↓(I); ↑(C)]
 NRSOR, 0.27; 95% CI, 0.09–0.87; p = 0.03 [↓(I); ↑(C)]
 OSOR, 0.40; 95% CI, 0.27–0.60; p < 0.00001 [↓(I); ↑(C)]
Coveringp = 0.33
 C-BLBOR, 0.13; 95% CI, 0.02–1.12; p = 0.06
 FSOR, 0.39; 95% CI, 0.28–0.54; p < 0.00001 [↓(I); ↑(C)]
Age groupp = 0.40
 AdultOR, 0.39; 95% CI, 0.28–0.55; p < 0.00001 [↓(I); ↑(C)]
 PediatricOR, 0.24; 95% CI, 0.08–0.69; p = 0.008 [↓(I); ↑(C)]
Anastomotic locationp = 0.63
 EsophagusOR, 0.28; 95% CI, 0.15–0.55; p = 0.0002 [↓(I); ↑(C)]
 Esophagojejunal or gastrojejunalOR, 0.28; 95% CI, 0.12–0.67; p = 0.004 [↓(I); ↑(C)]
 Gastrojejunal (bariatric surgery)OR, 0.19; 95% CI, 0.02–1.58; p = 0.12
 ColorectalOR, 0.47; 95% CI, 0.31–0.71; p = 0.0004 [↓(I); ↑(C)]
 MiscellaneousOR, 0.38; 95% CI, 0.28–0.51; p = 0.06
Indication for surgeryp = 0.66
 Malignant tumorOR, 0.40; 95% CI, 0.28–0.58; p< 0.00001 [↓(I); ↑(C)]
 Obesity (bariatric surgery)OR, 0.19; 95% CI, 0.02–1.58; p = 0.12
 MiscellaneousOR, 0.31; 95% CI, 0.15–0.63; p = 0.001 [↓(I); ↑(C)]
Indication for surgery (subclassified)p = 0.45
 Upper GIT malignancyOR, 0.26; 95% CI, 0.12–0.56; p= 0.0005 [↓(I); ↑(C)]
 Lower GIT malignancyOR, 0.47; 95% CI, 0.31–0.71; p= 0.0004 [↓(I); ↑(C)]
 Obesity (bariatric surgery)OR, 0.19; 95% CI, 0.02–1.58; p = 0.12
 MiscellaneousOR, 0.31; 95% CI, 0.15–0.63; p = 0.001 [↓(I); ↑(C)]

Subgroup analyses of fixed-effects meta-analysis for postoperative anastomotic leakage.

↓, Significantly lower; ↑, significantly higher; I, intervention group (coated or reinforced anastomoses); C, control group; RCT, randomized controlled trial; NRS, nonrandomized study; OS, observational study; C-BLB, collagen-based laminar biomaterial; FS, fibrin sealant; GIT, gastrointestinal tract. The bold indicates significant outcomes.

Postoperative Reoperation Rates

A total of five studies (37, 39, 51, 55, 58) examined the postoperative reoperation rates, occurring in seven (1.7%) of 405 patients in the intervention group and 39 (5.9%) of 663 patients in the control group. Rates of reoperation presented to be significantly lower for patients in the intervention group using fixed-effects meta-analysis (OR, 0.21; 95% CI, 0.10–0.47; p = 0.0001) (Figure 3).

Figure 3

Studies were homogeneous (I2 = 0%; p = 0.88), and results remained stable in sensitivity analyses. Subgroup analyses found no subgroup differences for subgroups stratified by study design (TSD: p = 0.71), intervention used (TSD: p = 0.60), anastomotic location (TSD: p = 0.64), and indication for surgery (TSD: p = 0.64) (Table 6).

Table 6

Postoperative reoperationOdds ratio (OR): fixed-effects modelHeterogeneity
OverallOR, 0.21; 95% CI, 0.10–0.47; p = 0.0001 [↓(I); ↑(C)]I2 = 0%; p = 0.88
Sensitivity analyses
Excluded studyOR: fixed-effects modelHeterogeneity
Grieder et al. (51)OR, 0.18; 95% CI, 0.07–0.48; p = 0.0007 [↓(I); ↑(C)]I2 = 0%; p = 0.82
Liu et al. (37)OR, 0.21; 95% CI, 0.09–0.48; p = 0.0002 [↓(I); ↑(C)]I2 = 0%; p = 0.76
Oliver et al. (55)OR, 0.21; 95% CI, 0.08–0.57; p = 0.002 [↓(I); ↑(C)]I2 = 0%; p = 0.76
Silecchia et al. (39)OR, 0.25; 95% CI, 0.11–0.58; p = 0.001 [↓(I); ↑(C)]I2 = 0%; p = 0.96
Torres-Melero et al. (58)OR, 0.20; 95% CI, 0.08–0.46; p = 0.0002 [↓(I); ↑(C)]I2 = 0%; p = 0.81
Subgroup analyses
SubgroupOR: fixed-effects modelTest for subgroup difference
Study designp = 0.71
 RCTOR, 0.15; 95% CI, 0.04–0.49; p = 0.002 [↓(I); ↑(C)]
 NRSOR, 0.27; 95% CI, 0.04–1.65; p = 0.16
 OSOR, 0.30; 95% CI, 0.08–1.14; p = 0.08
Coveringp = 0.60
 C-BLBOR, 0.38; 95% CI, 0.04–3.95; p = 0.42
 FSOR, 0.20; 95% CI, 0.08–0.46; p = 0.0002 [↓(I); ↑(C)]
Age group (adults only)
Anastomotic locationp = 0.64
 Gastrojejunal (bariatric surgery)OR, 0.11; 95% CI, 0.01–0.81; p = 0.03 [↓(I); ↑(C)]
 ColorectalOR, 0.32; 95% CI, 0.10–1.02; p = 0.05 [↓(I); ↑(C)]
 MiscellaneousOR, 0.20; 95% CI, 0.05–0.77; p = 0.02 [↓(I); ↑(C)]
Indication for surgeryp = 0.64
 Malignant tumor (lower GIT)OR, 0.32; 95% CI, 0.10–1.02; p= 0.05 [↓(I); ↑(C)]
 Obesity (bariatric surgery)OR, 0.11; 95% CI, 0.01–0.81; p = 0.03 [↓(I); ↑(C)]
 MiscellaneousOR, 0.20; 95% CI, 0.05–0.77; p = 0.02 [↓(I); ↑(C)]

Fixed-effects meta-analysis for postoperative reoperation in the intervention and control group.

↓, Significantly lower; ↑, significantly higher; I, intervention group (coated or reinforced anastomoses); C, control group; RCT, randomized controlled trial; NRS, nonrandomized study; OS, observational study; C-BLB, collagen-based laminar biomaterial; FS, fibrin sealant; GIT, gastrointestinal tract.The bold indicates significant outcomes.

Overall Postoperative Clavien–Dindo Major Complication Rates

Two studies (50, 52) evaluated the incidence of postoperative major complications according to the Clavien–Dindo classification of surgical complications (43). In total, 30 (10.4%) of 288 patients with external anastomotic coating and 95 (17.4%) of 545 patients in the control group developed postoperative C-DMC. The intervention group presented with significantly lower C-DMC rates using fixed-effects meta-analysis (OR, 0.54; 95% CI, 0.35–0.84; p = 0.006). Studies were homogeneous (I2 = 0%; p = 0.54) (Figure 4).

Figure 4

Length of Hospitalization

Another seven studies (34, 36, 38, 39, 52, 54, 57) monitored the length of hospitalization. The overall length of hospitalization was significantly shorter for patients in the intervention group compared to those for patients in the control group using the random-effects model meta-analysis to calculate the weighted mean difference (WMD, −1.96; 95% CI: −3.21, −0.71; p = 0.002). Studies showed significant substantial heterogeneity (I2 = 88%; p < 0.00001) but remained stable throughout sensitivity analyses. Subgroup analyses found a significant subgroup difference when the patients were stratified according to the intervention used (TSD: p = 0.0010), anastomotic location (TSD: p < 0.00001), indication for surgery (TSD: p = 0.001), and its subclassification (TSD: p = 0.001) (Figure 5).

Figure 5

Patients in the intervention group presented with a significantly shorter time of hospitalization compared to the control group if undergoing intestinal surgical procedures for malignant gastrointestinal tumors (WMD, −3.06; 95% CI: −4.93, −1.19; p = 0.001), especially if they were located in the upper GIT (WMD, −4.94; 95% CI: −7.98, −1.90; p = 0.001) and were operated with the creation of an esophagojejunal or gastrojejunal anastomosis (WMD, −2.28; 95% CI: −6.35, −4.31; p < 0.00001) (Table 7).

Table 7

Length of hospitalizationWeighted mean difference (WMD): random-effects modelHeterogeneity
OverallWMD, −1.96; 95% CI: −3.21, −0.71; p = 0.002 [↓(I); ↑(C)]I2 = 88%; p < 0.00001
Sensitivity analyses
Excluded studyWMD: random-effects modelHeterogeneity
Fernandez et al. (34)WMD, −1.48; 95% CI: −2.62, −0.33; p = 0.01 [↓(I); ↑(C)]I2 = 86%; p < 0.00001
Huang et al. (52)WMD, −1.90; 95% CI: −3.24, −0.55; p = 0.006 [↓(I); ↑(C)]I2 = 89%; p < 0.00001
Huh et al. (36)WMD, −2.50; 95% CI: −4.21, −0.79; p = 0.004 [↓(I); ↑(C)]I2 = 90%; p < 0.00001
Marano et al. (54)WMD, −1.36; 95% CI: −2.46, −0.25; p = 0.02 [↓(I); ↑(C)]I2 = 84%; p < 0.00001
Saldaña-Cortés et al. (38)WMD, −2.28; 95% CI: −3.68, −0.87; p = 0.001 [↓(I); ↑(C)]I2 = 90%; p < 0.00001
Sieda et al. (57)WMD, −1.99; 95% CI: −3.41, −0.57; p = 0.006 [↓(I); ↑(C)]I2 = 88%; p < 0.00001
Silecchia et al. (39)WMD, −2.53; 95% CI: −4.12, −0.94; p = 0.002 [↓(I); ↑(C)]I2 = 86%; p < 0.00001
Subgroup analyses
SubgroupWMD: random-effects modelTest for subgroup difference
Study designp = 0.22
 RCTWMD, −3.44; 95% CI: −10.62, 3.74; p = 0.35
 NRSWMD, −0.30; 95% CI: −2.01, 1.41; p = 0.73
 OSWMD, −2.36; 95% CI: −4.10, −0.61; p = 0.008 [↓(I); ↑(C)]
Coveringp = 0.0010
 C-BLBWMD, −5.90; 95% CI: −8.37, −3.43; p < 0.00001 [↓(I); ↑(C)]
 FSWMD, −1.36; 95% CI: −2.46, −0.25; p = 0.02 [↓(I); ↑(C)]
Age groupp = 0.08
 AdultWMD, −2.28; 95% CI: −3.68, −0.87; p = 0.001 [↓(I); ↑(C)]
 PediatricWMD, −0.30; 95% CI: −2.01, 1.41; p = 0.73
Anastomotic locationp < 0.00001
 EsophagusWMD, −1.34; 95% CI: −3.39, 0.72; p = 0.2
 Esophagojejunal or gastrojejunalWMD, −2.28; 95% CI: −6.35, −4.31; p < 0.00001 [↓(I); ↑(C)]
 Gastrojejunal (bariatric surgery)WMD, 0.0; 95% CI: −0.47, 0.47; p = 1.0
 ColorectalWMD, −1.15; 95% CI: −2.76, 0.47; p = 0.16
Indication for surgeryp = 0.008
 Malignant tumorWMD, −3.06; 95% CI: −4.93, −1.19; p = 0.001 [↓(I); ↑(C)]
 Obesity (bariatric surgery)WMD, 0.0; 95% CI: −0.47, 0.47; p = 1.0
 MiscellaneousWMD, −0.30; 95% CI: −2.01, 1.41; p = 0.73
Indication for surgery (subclassified)p = 0.010
 Upper GIT malignancyWMD, −4.94; 95% CI: −7.98, −1.90; p = 0.001 [↓(I); ↑(C)]
 Lower GIT malignancyWMD, −1.15; 95% CI: −2.76, 0.47; p = 0.16
 Obesity (bariatric surgery)WMD, 0.0; 95% CI: −0.47, 0.47; p = 1.0
 MiscellaneousWMD, −0.30; 95% CI: −2.01, 1.41; p = 0.73

Random-effects meta-analysis for the length of hospitalization in the intervention and control group.

↓, Significantly lower; ↑, significantly higher; I, intervention group (coated or reinforced anastomoses); C, control group; RCT, randomized controlled trial; NRS, nonrandomized study; OS, observational study; C-BLB, collagen-based laminar biomaterial; FS, fibrin sealant; GIT, gastrointestinal tract.The bold indicates significant outcomes.

Postoperative Mortality Rate

In total, four studies recorded postoperative mortality rates (38, 40, 52, 55), occurring in six (3.4%) of 174 patients with fibrin sealant-coated anastomoses and 13 (5.5%) of 240 patients in the control group. No significant differences were found between the studied groups using fixed-effects meta-analysis (OR, 0.52; 95% CI, 0.20–1.39; p = 0.19) (Figure 6).

Figure 6

Studies were homogeneous (I2 = 0%; p = 0.69) and remained stable in sensitivity analyses. Subgroup analyses found no significant subgroup difference for subgroups stratified by study design (TSD: p = 0.66), age group (TSD: p = 0.78), anastomotic location (TSD: p = 0.59), and indication for surgery (TSD: p = 0.74) (Table 8).

Table 8

MortalityOdds ratio (OR): fixed-effects modelHeterogeneity
OverallOR, 0.52; 95% CI, 0.20–1.39; p = 0.19I2 = 0%; p = 0.69
Sensitivity analyses
Excluded studyOR: fixed-effects modelHeterogeneity
Huang et al. (52)OR, 0.56; 95% CI, 0.20–1.59; p = 0.28I2 = 0%; p = 0.51
Oliver et al. (55)OR, 0.42; 95% CI, 0.12–1.52; p = 0.19I2 = 0%; p = 0.55
Saldaña-Cortés et al. (38)OR, 0.44; 95% CI, 0.15–1.28; p = 0.13I2 = 0%; p = 0.70
Upadhyaya et al. (40)OR, 0.72; 95% CI, 0.22–2.42; p = 0.60I2 = 0%; p = 0.72
Subgroup analyses
SubgroupOR: Fixed-effects modelTest for subgroup difference
Study designp = 0.66
 RCTOR, 0.47; 95% CI, 0.15–1.46; p = 0.19
 NRSOR, 1.77; 95% CI, 0.10–30.71; p = 0.70
 OSOR, 0.32; 95% CI, 0.02–6.80; p = 0.47
Covering (FS only)
 Age groupp = 0.78
 AdultOR, 0.60; 95% CI, 0.15–2.31; p = 0.46
 PediatricOR, 0.45; 95% CI, 0.11–1.87; p = 0.27
Anastomotic Locationp = 0.59
 EsophagusOR, 0.42; 95% CI, 0.12–1.52; p = 0.19
 MiscellaneousOR, 0.73; 95% CI, 0.16–3.46; p = 0.70
Indication for Surgeryp = 0.74
Malignant Tumor (upper GIT)OR, 0.32; 95% CI, 0.02–6.8; p = 0.47
 MiscellaneousOR, 0.56; 95% CI, 0.20–1.59; p = 0.28

Fixed-effects meta-analysis for postoperative mortality in the intervention and control goup.

RCT, randomized controlled trial; NRS, nonrandomized study; OS, observational study; FS, fibrin sealant; GIT, gastrointestinal tract.

Discussion

This systematic review and meta-analysis gives an overview of the efficacy of externally covering anastomoses with collagen-based laminar biomaterials or fibrin sealants in reducing postoperative rates of AL and its accompanying sequelae for patients undergoing surgery with the formation of an intestinal anastomosis.

The meta-analyses found significant differences for postoperative AL (Figure 2), reoperation rates (Figure 3), C-DMC (43) (Figure 4), and length of hospitalization (Figure 5). However, no significant differences between the studied groups were found in the postoperative mortality rate, even after conducting sensitivity and subgroup analyses (Figure 6 and Table 8).

A significant decrease in AL (Figure 2; Tables 4 and 5) and reoperation rate (Figure 3; Table 6) was found for patients with intestinal anastomoses covered either by collagen-based laminar biomaterials or by fibrin sealants. Sensitivity analyses confirmed the stability of these results. Subgroup analyses did not find any difference between the collagen-based laminar biomaterials and fibrin sealants in regard to their protective action. Furthermore, the outcomes remained significant regardless of the study design, age group studied, location of anastomoses, or indication of surgery. Postoperative major complications, according to the Clavien–Dindo classification for surgical complications (43), were shown to be significantly lower in the intervention group than those in the control group. Since only two studies (50, 52) reported complications categorized by this classification, no sensitivity or subgroup analysis could be conducted (Figure 4).

The length of hospitalization appeared to be significantly shorter for patients in the intervention group (Figure 5). These results remained stable throughout sensitivity analyses, and subgroup analyses did not find differences between subgroups stratified by study design, intervention used, or age group. However, a significant subgroup difference was observed for subgroups stratified by the location of anastomoses and the indication for surgery. In comparison to the control group, patients in the intervention group presented with a significantly shorter time of hospitalization if undergoing intestinal surgery with esophagojejunal or gastrojejunal anastomoses or if the indication for surgery was a malignant tumor, especially the case with upper gastrointestinal malignancies (Table 7).

No difference between the intervention and control group could be found in regard to postoperative mortality rates, even after performing sensitivity and subgroup analyses (Figure 6; Table 8). This outcome should be interpreted with caution, as not all studies reporting AL also reported postoperative mortality rates. To evaluate the effect of coating intestinal anastomoses with collagen-based laminar biomaterials or fibrin sealants on postoperative mortality rates, future studies should allow a longer follow-up for their patients to ensure postoperative mortality is not missed.

On the downside of the ambiguous outcomes presented in different experimental animal studies (2231, 33, 59, 60), fibrin sealants have been utilized already in human trials, showing positive effects. Sealing postoperatively occurring anastomotic leaks of the upper and lower GIT with fibrin sealants endoscopically has been conducted with successful therapeutic outcomes (6163). Endoscopic applications have shown to reduce exudation from the leakage site, systemic inflammatory response, and clinical symptoms of treated patients (61) and seem to serve as an efficient and safe option to manage postoperative ALs (62).

Furthermore, a recently published systematic review reported mainly positive effects on AL prevention and treatment upon covering esophageal anastomoses with collagen-based laminar biomaterials or fibrin sealants (64). Promising effects for staple-line reinforcement with absorbable materials such as fibrin sealants were reported as well for colorectal procedures (65). In the case of bariatric surgical procedures, Chen et al. (66) conducted a meta-analysis of six randomized controlled trials examining the effect of staple-line and anastomotic reinforcement with fibrin sealants on postoperative complications in morbidly obese patients undergoing laparoscopic sleeve gastrectomy or Roux-en-Y-gastric bypass. The authors demonstrated no significant difference between the studied groups’ postoperative AL rates. These results coincide with our findings after conducting a subgroup analysis stratified by indication for surgery. Still, precautions should be taken to compare the results of our subgroup analysis with those of the previously conducted meta-analysis (66), as our study excluded any surgical procedure without the formation of an intestinal anastomosis.

Interestingly, Panda et al. conducted a cost analysis, evaluating the differences in economic burden in regard to resource expenses provided by the healthcare system upon covering colorectal anastomoses with fibrin sealants. The authors concluded that the application of fibrin sealants was not only associated with decreased AL rates but also contributed to cost savings of roughly 22% (using a potential model). These cost savings originate mainly from the reduction in the length of hospitalization due to postoperative reoperations, radiological interventions, and/or transfusions (67). These findings correlate with the observed outcomes of our investigation.

This study showed that coating intestinal anastomoses with collagen-based laminar biomaterials or fibrin sealants resulted in significantly reduced postoperative AL, reoperation, C-DMC rates, and shorter length of hospitalization; nevertheless, there is still room for improvement. A large proportion of postoperative anastomotic leaks is associated with anastomotic infections (68). In a recent study, Anderson et al. (68) investigated cultures of 19 patients with AL and found 74% of these patients' leaks to be colonized with collagenase-producing microorganisms. Furthermore, the authors found the presence of Enterococcus faecalis to be significantly associated with the development of AL (68). In the physiology of anastomotic wound healing, the risk of wound failure corresponds to the activity of collagenases (69). As collagen deposition plays a crucial role in adequate anastomotic healing (70), an infection of the anastomosis leads to collagenase enzyme activities exceeding the physiological levels needed for proper wound healing, contributing to anastomotic failure (69, 71). Furthermore, such infections could potentially compromise the functionality of anastomotic coatings with collagen-based laminar biomaterials due to the destructive effect of these microorganisms’ collagenases on the biomaterial’s basic framework. To assure the complete functionality of these adhesive biomaterials and adequate anastomotic healing, infections should be prevented. If sealants would contain both the healing supporting collagen fibrils and antimicrobial substances, effectively protecting the anastomoses and the adhesives from collagenase-producing microorganisms, theoretically, a much higher effect for further reducing postoperative anastomotic complications could be expected.

The results of our analysis have limitations that need to be addressed. The included studies presented with variable study designs and years of publication (1996–2021) and were of moderate quality in most cases. We decided to include studies older than 15 years (34, 37, 39, 40) in our analysis as their interventions are comparable to interventions of studies conducted in the following years and the adhesive biomaterials used correspond to those used in more recent studies. Different types and materials of sealants were compared among patients with different characteristics, such as different age groups and surgical indications, which could have introduced potential biases to our analysis. We addressed this limitation by performing thorough subgroup analyses stratified by these potential confounding factors and investigating the stability of our results by conducting sensitivity analyses, regardless of the observed heterogeneity. Additional sources of potential bias were the possible lack of adequate blinding since none of the five RCTs (34, 39, 40, 55, 56) and three NRSs (37, 38, 58) commented on the outcome assessor’s awareness of intervention, and the potential influence the manufacturer of the adhesive biomaterials used might have had by funding the study. We carefully examined the funding situations with regard to each included study and have come to the conclusion that the manufacturer—to our knowledge—did not present a funding role in any of the included studies nor was an author mentioned to be a representative for the manufacturer. Furthermore, our analysis did not evaluate the effect of coating other types of anastomoses commonly performed in abdominal surgery, such as pancreaticointestinal or biliodigestive anastomoses. Since these types of anastomoses present distinct differences in surgical techniques and specific risks for AL and its associated morbidities, we excluded all types of anastomoses other than intestinal anastomoses of the upper and lower GIT. The risk of biasing the results of our study's observed outcomes would have been potentiated by including these types of anastomoses in our study. Therefore, we did not evaluate these kinds of effects in the present analysis but would recommend analyzing the effects of coating other types of anastomoses commonly performed in abdominal surgery on postoperative complications separately in a further systematic review and meta-analysis in the future.

However, the strength of this study is its uniqueness since this is the first systematic review with a meta-analysis investigating the efficacy of coating intestinal anastomoses with the most commonly utilized absorbable adhesives (20, 21) in reducing postoperative AL rates and its accompanying sequelae.

The outcomes of this systematic review and meta-analysis present some clinical implications and justify the need for future research to consolidate our findings. Furthermore, larger RCTs examining the effects of the studied adhesives in the context of different surgical indications and patient groups need to be conducted. One could ask why coating of intestinal anastomoses with collagen-based laminar biomaterials and/or fibrin sealants has yet not been established in everyday clinical practice. Possible reasons could be the difficult and user-unfriendly application form resulting in additional time expenditure or the low adhesive strength of these biomaterials on intestinal surfaces. Since these adhesive biomaterials have shown significant efficacy in reducing postoperative morbidity after intestinal surgery, future research and innovative developments should address these unfavorable factors.

In conclusion, current evidence suggests that covering intestinal anastomoses with either collagen-based laminar biomaterials or fibrin sealants significantly reduces postoperative rates of AL, reoperation, and C-DMC. Furthermore, with these adhesives, a significant reduction in the length of hospitalization can be observed, especially for patients undergoing surgery for an upper gastrointestinal malignancy. Still, the risk of anastomotic and potential adhesive failure associated with anastomotic infection should be addressed, by investigating the efficacy of antimicrobial collagen-based sealants, for protecting intestinal anastomoses from the deleterious effect of collagenase-producing microorganisms. To consolidate our findings, there is a need for further large RCTs examining the effects of coating intestinal anastomoses with the studied adhesives on postoperative leakage. Aside from that, the effect of coating other types of anastomoses commonly performed in abdominal surgery on postoperative complications should be investigated in future studies. Finally, a simple and user-friendly application form of a somewhat stronger adhesive collagen-based laminar biomaterial and/or fibrin sealant should be developed to establish the possibility of routine use in surgical practice.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material further inquiries can be directed to the corresponding author/s.

Author contributions

KC, FS, SR, and P-AN contributed to the conception and design of the study. KC and FS were involved in data collection and quantitative and qualitative analyses. SR and P-AN assessed the accuracy of the data. KC organized the database. KC performed the statistical analysis. KC created figures and tables. KC drafted the manuscript. FS, SR, P-AN, AO, RB, and HF revised the manuscript for important intellectual contents. All authors contributed to manuscript revision, read, and approved the submitted version. P-AN and RB were responsible for funding.

Funding

This study was supported by the Bavarian Research Foundation (Grant No. AZ-1508-21).

Acknowledgments

The authors acknowledge Bernhard Haller, Research Associate at the Institute for Epidemiology and Medical Statistics of the Technical University of Munich, Munich, Bavaria, Germany, for providing statistical consulting.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fsurg.2022.882173/full#supplementary-material.

Supplementary Table 1 | Search strategy. Final database search (January 17, 2022).

Supplementary Table 2 | Risk of bias assessment for included studies (abstracts excluded).

References

  • 1.

    SchmidtHMGisbertzSSMoonsJRouvelasIKauppiJBrownAet alDefining benchmarks for transthoracic esophagectomy: a multicenter analysis of total minimally invasive esophagectomy in low risk patients. Ann Surg. (2017) 266(5):81421. 10.1097/sla.0000000000002445

  • 2.

    StrueckerBAndreouAChopraSHeilmannACSpenkeJDeneckeCet alEvaluation of anastomotic leak after esophagectomy for esophageal cancer: typical time point of occurrence, mode of diagnosis, value of routine radiocontrast agent studies and therapeutic options. Dig Surg. (2018) 35(5):41926. 10.1159/000480357

  • 3.

    van WorkumFvan der MaasJvan den WildenbergFJPolatFKouwenhovenEAvan DetMJet alImproved functional results after minimally invasive esophagectomy: intrathoracic versus cervical anastomosis. Ann Thorac Surg. (2017) 103(1):26773. 10.1016/j.athoracsur.2016.07.010

  • 4.

    DoeksenATanisPJVrouenraetsBCGooszenJAvan LanschotJJvan TetsWF. Outcome of rectal cancer surgery after the introduction of preoperative radiotherapy in a low-volume hospital. J Gastrointest Cancer. (2007) 38(2–4):6370. 10.1007/s12029-008-9018-y

  • 5.

    LindnerKFritzMHaaneCSenningerNPalmesDHummelR. Postoperative complications do not affect long-term outcome in esophageal cancer patients. World J Surg. (2014) 38(10):265261. 10.1007/s00268-014-2590-3

  • 6.

    SeesingMFJGisbertzSSGoenseLvan HillegersbergRKroonHMLagardeSMet alA propensity score matched analysis of open versus minimally invasive transthoracic esophagectomy in the Netherlands. Ann Surg. (2017) 266(5):83946. 10.1097/sla.0000000000002393

  • 7.

    HagensERCReijntjesMAAndereggMCJEshuisWJvan Berge HenegouwenMIGisbertzSS. Risk factors and consequences of anastomotic leakage after esophagectomy for cancer. Ann Thorac Surg. (2021) 112(1):25563. 10.1016/j.athoracsur.2020.08.022

  • 8.

    KangCYHalabiWJChaudhryOONguyenVPigazziACarmichaelJCet alRisk factors for anastomotic leakage after anterior resection for rectal cancer. JAMA Surg. (2013) 148(1):6571. 10.1001/2013.jamasurg.2

  • 9.

    AkasuTTakawaMYamamotoSYamaguchiTFujitaSMoriyaY. Risk factors for anastomotic leakage following intersphincteric resection for very low rectal adenocarcinoma. J Gastrointest Surg. (2010) 14(1):10411. 10.1007/s11605-009-1067-4

  • 10.

    WatanabeMMiyataHGotohMBabaHKimuraWTomitaNet alTotal gastrectomy risk model: data from 20,011 Japanese patients in a nationwide internet-based database. Ann Surg. (2014) 260(6):10349. 10.1097/sla.0000000000000781

  • 11.

    MirnezamiAMirnezamiRChandrakumaranKSasapuKSagarPFinanP. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. (2011) 253(5):8909. 10.1097/SLA.0b013e3182128929

  • 12.

    KrarupPMNordholm-CarstensenAJorgensenLNHarlingH. Anastomotic leak increases distant recurrence and long-term mortality after curative resection for colonic cancer: a nationwide cohort study. Ann Surg. (2014) 259(5):9308. 10.1097/SLA.0b013e3182a6f2fc

  • 13.

    HammondJLimSWanYGaoXPatkarA. The burden of gastrointestinal anastomotic leaks: an evaluation of clinical and economic outcomes. J Gastrointest Surg. (2014) 18(6):117685. 10.1007/s11605-014-2506-4

  • 14.

    AleksandrovVBKapullerLLPoliakovaAMBaranchikovVISlavin IuM. The reaction of intestinal wall tissue to several types of cyacrin glue and its combined use with mechanical tantalum suture in anterior resection of the rectum (experimental study). Eksp Khir Anesteziol. (1971) 16(2):4650.

  • 15.

    VishnevskiĭAA Jr. An instrument for intestinal anastomosis with the use of glue. Eksp Khir Anesteziol. (1966) 11(5):212.

  • 16.

    RuscaJABornsideGHCohnI Jr. Everting versus inverting gastrointestinal anastomoses: bacterial leakage and anastomotic disruption. Ann Surg. (1969) 169(5):72735. 10.1097/00000658-196905000-00010

  • 17.

    AndersABodemannTBaerUBauknechtKJLawerenzJU. Are fibrin adhesive and collagen fleece additional protective measures for colon anastomoses?Langenbecks Arch Chir. (1981) 1981(Suppl.):17580. 10.1007/978-3-642-68016-8_35

  • 18.

    ScheeleJHerzogJMueheE. Fibrin glue protection of digestive anastomoses. Zentralbl Chir. (1978) 103(20):132536.

  • 19.

    SpotnitzWD. Fibrin sealant: the only approved hemostat, sealant, and adhesive – a laboratory and clinical perspective. ISRN Surg. (2014) 2014:203943. 10.1155/2014/203943

  • 20.

    Takeda Pharma a/S. Tisseel [Fibrin Sealant][Package Insert]. U.S. Food and Drug Administration. Revised 2013 Available from: https://www.fda.gov/media/71674/download (Accessed January 26, 2022).

  • 21.

    Takeda Pharma a/S. Tachosil® Fibrin Sealant Patch)[Package Insert]. U.S. Food and Drug Administration. Revised July 2015. Available from:https://www.fda.gov/media/78698/download (Accessed January 26, 2022).

  • 22.

    ChmelnikMLaschLWeihSWinkERomeroPHolland-CunzS. Anastomotic sealing with a fibrin-coated collagen patch in small-diameter bowel. Langenbecks Arch Surg. (2011) 396(5):68591. 10.1007/s00423-011-0750-6

  • 23.

    Garcia-PerezRMunitizVMartinez-CaceresCMRuiz de AnguloDOrtizAMartinez de HaroLFet alHistopathological and immunohistochemical analysis of the use of collagen dressing as a reinforcement of esophagic anastomosis in a rat experimental model. Cir Esp. (2017) 95(10):58893. 10.1016/j.ciresp.2017.08.008

  • 24.

    HolmerCPraechterCMecklenburgLHeimesaatMRiegerHPohlenU. Anastomotic stability and wound healing of colorectal anastomoses sealed and sutured with a collagen fleece in a rat peritonitis model. Asian J Surg. (2014) 37(1):3545. 10.1016/j.asjsur.2013.07.008

  • 25.

    NordentoftTRømerJSørensenM. Sealing of gastrointestinal anastomoses with a fibrin glue-coated collagen patch: a safety study. J Invest Surg. (2007) 20(6):3639. 10.1080/08941930701772173

  • 26.

    PantelisDBeisselAKahlPWehnerSVilzTOKalffJC. The effect of sealing with a fixed combination of collagen matrix-bound coagulation factors on the healing of colonic anastomoses in experimental high-risk mice models. Langenbecks Arch Surg. (2010) 395(8):103948. 10.1007/s00423-010-0703-5

  • 27.

    PommergaardHCAchiamMPBurcharthJRosenbergJ. Decreased leakage rate of colonic anastomoses by tachosil coating: an experimental study. Int Surg. (2014) 99(4):35963. 10.9738/intsurg-d-13-00093.1

  • 28.

    SabinoFDCamposCFFCaetanoCERTrotteMNSOliveiraAVMarquesRG. Effects of tachosil and 5-fluorouracil on colonic anastomotic healing. J Surg Res. (2014) 192(2):37582. 10.1016/j.jss.2014.05.067

  • 29.

    SchreinemacherMHBloemenJGvan der HeijdenSJGijbelsMJDejongCHBouvyND. Collagen fleeces do not improve colonic anastomotic strength but increase bowel obstructions in an experimental rat model. Int J Colorectal Dis. (2011) 26(6):72935. 10.1007/s00384-011-1158-z

  • 30.

    StumpfMJungeKRoschRKronesCKlingeUSchumpelickV. Suture-free small bowel anastomoses using collagen fleece covered with fibrin glue in pigs. J Invest Surg. (2009) 22(2):13847. 10.1080/08941930802713001

  • 31.

    Suárez-GrauJMBernardos GarcíaCCepeda FrancoCMendez GarcíaCGarcía RuizSDocobo DurantezFet alFibrinogen–thrombin collagen patch reinforcement of high-risk colonic anastomoses in rats. World J Gastrointest Surg. (2016) 8(9):62733. 10.4240/wjgs.v8.i9.627

  • 32.

    VaneerdewegWHendriksJMLauwersPRIevenMEyskensEJ. Effect of gentamicin-containing sponges on the healing of colonic anastomoses in a rat model of peritonitis. Eur J Surg. (2000) 166(12):95962. 10.1080/110241500447137

  • 33.

    VerhageRJRuizAVerheemAGoldschmedingRBorel RinkesIHvan HillegersbergR. Fibrin-thrombin coated sealant increases strength of esophagogastric anastomoses in a rat model. J Surg Res. (2012) 176(2):e5763. 10.1016/j.jss.2011.12.028

  • 34.

    Fernandez FernandezLTejeroETiesoA. Randomized trial of fibrin glue to seal mechanical oesophagojejunal anastomosis. Br J Surg. (1996) 83(1):401. 10.1002/bjs.1800830111

  • 35.

    GriederFGelpkeHCadoschDDecurtinsM. Fibrin glue reduces the rate of anastomotic leakage in colorectal surgery. Br J Surg. (2010) 97:4.

  • 36.

    HuhJWKimHRKimYJ. Anastomotic leakage after laparoscopic resection of rectal cancer: the impact of fibrin glue. Am J Surg. (2010) 199(4):43541. 10.1016/j.amjsurg.2009.01.018

  • 37.

    LiuCDGlantzGJLivingstonEH. Fibrin glue as a sealant for high-risk anastomosis in surgery for morbid obesity. Obes Surg. (2003) 13(1):458. 10.1381/096089203321136575

  • 38.

    Saldaña-CortésJALarios-ArceoFPrieto-Díaz-ChávezEDe BuenEPGonzález-MercadoSAlvarez-VillaseñorASet alRole of fibrin glue in the prevention of cervical leakage and strictures after esophageal reconstruction of caustic injury. World J Surg. (2009) 33(5):98693. 10.1007/s00268-009-9949-x

  • 39.

    SilecchiaGBoruCEMouielJRossiMAnselminoMTacchinoRMet alClinical evaluation of fibrin glue in the prevention of anastomotic leak and internal hernia after laparoscopic gastric bypass: preliminary results of a prospective, randomized multicenter trial. Obes Surg. (2006) 16(2):12531. 10.1381/096089206775565249

  • 40.

    UpadhyayaVDGopalSCGangopadhyayaANGuptaDKSharmaSUpadyayaAet alRole of fibrin glue as a sealant to esophageal anastomosis in cases of congenital esophageal atresia with tracheoesophageal fistula. World J Surg. (2007) 31(12):24125. 10.1007/s00268-007-9244-7

  • 41.

    HigginsJPTThomasJChandlerJCumpstonMLiTPageMJWelchVA, editors. Handbook for Systematic Reviews of Interventions. Version 6.2(updated February 2021) (2021). Available from:www.training.cochrane.org/handbook[Accessed January 26, 2022].

  • 42.

    PageMJMcKenzieJEBossuytPMBoutronIHoffmannTCMulrowCDet alThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 88, 372: 105906. 10.1016/j.ijsu.2021.105906

  • 43.

    DindoDDemartinesNClavienP-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. (2004) 240(2):20513. 10.1097/01.sla.0000133083.54934.ae

  • 44.

    SterneJACSavovićJPageMJElbersRGBlencoweNSBoutronIet alRoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. (2019) 366:l4898, 10.1136/bmj.l4898

  • 45.

    SterneJAHernánMAReevesBCSavovićJBerkmanNDViswanathanMet alROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. (2016) 355:i4919. 10.1136/bmj.i4919

  • 46.

    WellsG. A.SheaB.O’ConnellD.PetersonJ.WelchV.LososM.et alThe Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses (2007). Available from:www.ohri.ca/programs/clinical_epidemiology/oxford.asp[Accessed January 26, 2022].

  • 47.

    McGrathSZhaoXSteeleRThombsBDBenedettiA. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. (2020) 9:18. 10.1177/0962280219889080

  • 48.

    HigginsJPThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21(11):153958. 10.1002/sim.1186

  • 49.

    EggerMDavey SmithGSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315(7109):62934. 10.1136/bmj.315.7109.629

  • 50.

    BrehantOSabbaghCLehertPDhahriARebiboLRegimbeauJM. The gentamicin–collagen sponge for surgical site infection prophylaxis in colorectal surgery: a prospective case-matched study of 606 cases. Int J Colorectal Dis. (2013) 28(1):11925. 10.1007/s00384-012-1557-9

  • 51.

    GriederFGelpkeHCadoschDDecurtinsM, editors. Fibrin glue reduces the rate of anastomotic leakage in colorectal surgery. Br J Surg. 2010.

  • 52.

    HuangYHuYLinYFuJWuJFangCet alEvaluation of fibrin sealant in prevention of cervical anastomotic leakage after McKeown esophagectomy: a single-center, retrospective study. Ann Surg Oncol. (2021) 28(11):63907. 10.1245/s10434-021-09877-0

  • 53.

    KimHJHuhJWKimHRKimYJ. Oncologic impact of anastomotic leakage in rectal cancer surgery according to the use of fibrin glue: case-control study using propensity score matching method. Am J Surg. (2014) 207(6):8406. 10.1016/j.amjsurg.2013.07.047

  • 54.

    MaranoLDi MartinoN. Efficacy of human fibrinogen–thrombin patch (tachosil) clinical application in upper gastrointestinal cancer surgery. J Invest Surg. (2016) 29(6):3528. 10.1080/08941939.2016.1181229

  • 55.

    OliverJLMedinaIAGarcia-AlmentaEMGilJMSanchezMSDiazMDPet alUse of fibrin based biological adhesives in the prevention of anastomotic leaks in the high risk digestive tract: preliminary results of the multicentre, prospective, randomised, controlled, and simple blind phase IV clinical trial: Protissucol001. Cir Esp. (2012) 90(10):64755. 10.1016/j.ciresp.2012.05.007

  • 56.

    SdralisETzaferaiADavakisSSyllaiosAKordzadehALorenziBet alReinforcement of intrathoracic oesophago-gastric anastomosis with fibrin sealant (Tisseel®) in oesophagectomy for cancer: a prospective comparative study. Am J Surg. (2020) 219(1):1238. 10.1016/j.amjsurg.2019.06.013

  • 57.

    SiedaBGharibO. Comparative study of single-layer anastomosis in high-risk colonic anastomosis versus single layer reinforced using fibrin glue. Egypt J Surg. (2015) 34:215. 10.4103/1110-1121.167380

  • 58.

    Torres-MeleroJMotos-MicóJJLorenzo-LiñánMMorales-GonzálezÁRosado-CobiánR. Use of absorbable fibrin sealant patch to strengthen the gastrointestinal anastomosis performed on patients with peritoneal carcinomatosis treated with intention to cure by debulking surgery and intraoperative hyperthermic intraperitoneal chemotherapy. Cir Cir. (2016) 84(2):1028. 10.1016/j.circir.2015.09.005

  • 59.

    PommergaardHCAchiamMPRosenbergJ. External coating of colonic anastomoses: a systematic review. Int J Colorectal Dis. (2012) 27(10):124758. 10.1007/s00384-012-1547-y

  • 60.

    NordentoftTPommergaardHCRosenbergJAchiamMP. Fibrin glue does not improve healing of gastrointestinal anastomoses: a systematic review. Eur Surg Res. (2015) 54(1–2):113. 10.1159/000366418

  • 61.

    ChenXYuanXChenZZhuL. Endoscopic injection of human fibrin sealant in treatment of intrathoracic anastomotic leakage after esophageal cancer surgery. J Cardiothorac Surg. (2020) 15(1):96. 10.1186/s13019-020-01127-w

  • 62.

    Del RioPDell’AbatePSolianiPZieglerSArcuriMSianesiM. Endoscopic treatment of esophageal and colo-rectal fistulas with fibrin glue. Acta Biomed. (2005) 76(2):958.

  • 63.

    LippertEKleblFHSchwellerFOttCGelbmannCMSchölmerichJet alFibrin glue in the endoscopic treatment of fistulae and anastomotic leakages of the gastrointestinal tract. Int J Colorectal Dis. (2011) 26(3):30311. 10.1007/s00384-010-1104-5

  • 64.

    PlatVDBootsmaBTvan der WielenNStraatmanJSchoonmadeLJvan der PeetDLet alThe role of tissue adhesives in esophageal surgery: a systematic review of literature. Int J Surg. (2017) 40:1638. 10.1016/j.ijsu.2017.02.093

  • 65.

    CheragwandiANieuwenhuisDHGagnerMConstenEC. An update of available innovative staple line reinforcement materials in colorectal surgery. Surg Technol Int. (2008) 17:1317.

  • 66.

    ChenY-SLohE-WShenS-CSuY-HTamK-W. Efficacy of fibrin sealant in reducing complication risk after bariatric surgery: a systematic review and meta-analysis. Obes Surg. (2021) 31(3):115867. 10.1007/s11695-020-05098-8

  • 67.

    PandaSConnollyMPRamirezMGde HerediaJB. Costs analysis of fibrin sealant for prevention of anastomotic leakage in lower colorectal surgery. Risk Manage Healthc Policy. (2020) 13:511. 10.2147/RMHP.S221008

  • 68.

    AndersonDIKeskeyRAckermanMTZaborinaOHymanNAlverdyJCet alEnterococcus faecalis is associated with anastomotic leak in patients undergoing colorectal surgery. Surg Infect (Larchmt). (2021) 22(10):104751. 10.1089/sur.2021.147

  • 69.

    ThompsonSKChangEYJobeBA. Clinical review: healing in gastrointestinal anastomoses, Part I. Microsurgery. (2006) 26(3):1316. 10.1002/micr.20197

  • 70.

    NeumannPATwardyVBeckerFGeyerCSchwegmannKMohrAet alAssessment of MMP-2/-9 expression by fluorescence endoscopy for evaluation of anastomotic healing in a murine model of anastomotic leakage. PLoS One. (2018) 13(3):e0194249. 10.1371/journal.pone.0194249

  • 71.

    ThorntonFJBarbulA. Healing in the gastrointestinal tract. Surg Clin North Am. (1997) 77(3):54973. 10.1016/s0039-6109(05)70568-5

Summary

Keywords

intestinal anastomoses, coated collagen patch, fibrin sealant, fibrin glue (FG), anastomotic leakage (AL)

Citation

Cira K, Stocker F, Reischl S, Obermeier A, Friess H, Burgkart R and Neumann P-A (2022) Coating of Intestinal Anastomoses for Prevention of Postoperative Leakage: A Systematic Review and Meta-Analysis. Front. Surg. 9:882173. doi: 10.3389/fsurg.2022.882173

Received

23 February 2022

Accepted

05 April 2022

Published

22 April 2022

Volume

9 - 2022

Edited by

Sven Flemming, University Hospital of Wuerzburg, Germany

Reviewed by

Michael Meir, University Hospital Würzburg, Germany Ulf Gunnarsson, Umeå University, Sweden

Updates

Copyright

*Correspondence: Kamacay Cira

ORCID: Philipp-Alexander Neumann orcid.org/0000-0001-8361-3934 Stefan Reischl orcid.org/0000-0001-7341-4296

Speciality section: This article was submitted to Visceral Surgery, a section of the journal Frontiers in Surgery

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics